Fierce BioBiotech
AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent
21 Apr 20260 views
Summary
Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma. But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational biopharma in its own right.
Since its 2014 founding, Zai Lab has built its business by licensing drugs from Big Pharma. But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational biopharma in its own right.